These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9237497)

  • 61. [Current aspects of the diagnosis of malignant hyperthermia].
    Rüffert H; Olthoff D; Deutrich C; Froster UG
    Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phenotypes associated with malignant hyperthermia susceptibility in swine genotyped as homozygous or heterozygous for the ryanodine receptor mutation.
    Fletcher JE; Calvo PA; Rosenberg H
    Br J Anaesth; 1993 Sep; 71(3):410-7. PubMed ID: 8398525
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families.
    Iles DE; Lehmann-Horn F; Scherer SW; Tsui LC; Olde Weghuis D; Suijkerbuijk RF; Heytens L; Mikala G; Schwartz A; Ellis FR
    Hum Mol Genet; 1994 Jun; 3(6):969-75. PubMed ID: 7951247
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The genetic basis of malignant hyperthermia.
    Moochhala SM; Tan WT; Lee TL
    Ann Acad Med Singap; 1994 Jul; 23(4):475-8. PubMed ID: 7979121
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript.
    Loke JC; Kraev N; Sharma P; Du G; Patel L; Kraev A; MacLennan DH
    Anesthesiology; 2003 Aug; 99(2):297-302. PubMed ID: 12883402
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genetic variation in RYR1 and malignant hyperthermia phenotypes.
    Carpenter D; Robinson RL; Quinnell RJ; Ringrose C; Hogg M; Casson F; Booms P; Iles DE; Halsall PJ; Steele DS; Shaw MA; Hopkins PM
    Br J Anaesth; 2009 Oct; 103(4):538-48. PubMed ID: 19648156
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility.
    Johannsen S; Klingler W; Schneiderbanger D; Heiderich S; Roewer N; Schuster F
    Acta Anaesthesiol Scand; 2013 Oct; 57(9):1161-6. PubMed ID: 23957432
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genotype and phenotype relationships for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia.
    Fletcher JE; Tripolitis L; Hubert M; Vita GM; Levitt RC; Rosenberg H
    Br J Anaesth; 1995 Sep; 75(3):307-10. PubMed ID: 7547049
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores.
    Quane KA; Keating KE; Healy JM; Manning BM; Krivosic-Horber R; Krivosic I; Monnier N; Lunardi J; McCarthy TV
    Genomics; 1994 Sep; 23(1):236-9. PubMed ID: 7829078
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 71. 3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.
    Lacava C; Michalek-Sauberer A; Kraft B; Sgaragli G; Sipos E; Höller C; Kress HG; Fusi F; Weigl LG
    Pharmacol Res; 2012 Jul; 66(1):80-7. PubMed ID: 22480578
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
    Bina S; Cowan G; Karaian J; Muldoon S; Mongan P; Bünger R
    Anesthesiology; 2006 Jan; 104(1):90-100. PubMed ID: 16394695
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia.
    Wappler F; Scholz J; Köchling A; Steinfath M; Krause T; Schulte am Esch J
    Br J Anaesth; 1997 May; 78(5):541-7. PubMed ID: 9175969
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mg2+ dependence of halothane-induced Ca2+ release from the sarcoplasmic reticulum in skeletal muscle from humans susceptible to malignant hyperthermia.
    Duke AM; Hopkins PM; Halsal JP; Steele DS
    Anesthesiology; 2004 Dec; 101(6):1339-46. PubMed ID: 15564941
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
    Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
    PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype.
    Sambuughin N; McWilliams S; de Bantel A; Sivakumar K; Nelson TE
    Am J Hum Genet; 2001 Jul; 69(1):204-8. PubMed ID: 11389482
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of the segregation of the RYR1 C184OT mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Hogan K
    Anesthesiology; 1996 Feb; 84(2):29A-30A. PubMed ID: 8602659
    [No Abstract]   [Full Text] [Related]  

  • 79. A simple method to detect the RYR1 mutation G1021A, a cause of malignant hyperthermia susceptibility.
    Alestrøm A; Fagerlund TH; Berg K
    Clin Genet; 1995 May; 47(5):274-5. PubMed ID: 7554356
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.
    Wappler F; Roewer N; Köchling A; Scholz J; Löscher W; Steinfath M
    Anesthesiology; 1996 Jun; 84(6):1280-7. PubMed ID: 8669667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.